ఇమ్యునోలాజికల్ డిజార్డర్స్ మరియు ఇమ్యునోథెరపీ
అందరికి ప్రవేశం

నైరూప్య

The strategy of future vaccines to overcoming prevalence pathogens

Iraj Khalili

The strategy of future vaccines to overcoming prevalence pathogens

Iraj Khalili

ANAU University

Vaccination has been a remarkable success story in terms of saving lives and giving more people a chance of healthy and productive lives. Despite its success, the benefits of vaccination are still being missed by many. Consolidating the gains made during the Decade of Vaccines and establishing a new direction for the next decade and beyond, the Immunization Agenda 2030 is designed to revitalize efforts in the battle against infectious disease and sets a renewed.

Improvements towards the eradication of new emerge pathogens and the elimination of serious infection disease is currently too slow to achieve the healthy goals. Many of the vaccines still in use today were developed on an experimental basis, essentially following the paradigm established by Pasteur, “isolate, inactivate, and inject” the disease-causing microorganism, and are capable of eliciting uniform, long-term immune memory responses that constitute the key to their proven efficacy. However, vaccines for pathogens considered as priority targets of public health concern are still lacking. The literature watch over to focus more often on vaccine research problems associated with specific pathogens, but it is increasingly clear that there are common restrictions in vaccine research, which need to be solved in order to advance the development of the field as a whole. As part of a group of articles, the objective of the present report is to pinpoint these bottlenecks, exploring the literature for common problems and solutions in vaccine research applied to different situations. Our goal is to stimulate brainstorming among specialists of different fields related to vaccine research and development.